Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 6, 2007, Pages 709-714

  Cote G A ^a   Ferreira, M R ^a   Rozenberg Ben Dror, K ^b   Howden, C W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; COST SAVINGS; ESOPHAGITIS, PEPTIC; FEMALE; FORMULARIES, HOSPITAL; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMPS; TREATMENT FAILURE;

EID: 33847061970     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03248.x     Document Type: Article

References (28)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6.
2. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 69-73.
3. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med 1999; 72: 181-94.
4. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs. ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624-30.
5. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole vs. omeprazole in short-term treatment of reflux esophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993; 28: 224.
6. Thjodleiffsson B, Beker JA, Dekkers C, et al. Rabeprazole vs. omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multi-center, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45: 845.
7. Delchier JC, Cohen G, Humphries TJ. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastroesophageal reflux disease. Scand J Gastroenterol 2000; 35: 1245-50.
8. Chiba N, DeGara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in Grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroeneterology 1997; 112: 1798.
9. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803.
10. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810.
11. Van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2000, issue 2; CD0022095.
12. Dekkers C, Beker JA, Thjodleifsson B, et al. Double blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 49-57.
13. Delchier J, Cohen G, Humphries T, et al. Rabeprazole is comparable in efficacy to omeprazole in erosive GERD and provides more rapid heartburn relief. Gastroenterology 1998; 116: A146 (Abstract).
14. Beck IT. In support of 'step-up therapy' for gastroesophageal reflux disease. Am J Gastroenterol 2002; 97: 503-4.
15. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics 2002; 20: 565-76.
16. Pohland CJ, Scavnicky SA, Lasky SS, et al. Lansoprazole overutilization: methods for step-down therapy. Am J Manag Care 2003; 9: 353-8.
17. Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol 2005; 20: 1365-70.
18. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704-10.
19. Beglinger C, Thalmann C, Szucs T, Michetti P. Long-term treatment of patients with symptomatic gastroesophageal reflux disease comparing costs and efficacy over 6 month of treatment with nexium on-demand treatment or nexium continuous treatment. An open, randomised multi-center study. Schweiz Rundsch Med Prax 2006; 95: 483-7 (German).
20. Habu Y, Maeda K, Kusuda T, et al. "Proton-pump inhibitor-first" strategy vs. "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol 2005; 40: 1029-35.
21. Hansen AN, Wahlqvist P, Jorgensen E, et al. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms - a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005; 59: 655-64.
22. Morgan DG, O'Mahony MF, O'Mahony WF, et al. Maintenance Therapy with Continuous and On-Demand Rabeprazole (RAB) 20 mg in Uninvestigated Gastroesophageal Reflux Disease. Abstract Presented at Digestive Diseases Week, Los Angeles, CA, 2006.
23. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624-30.
24. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621-30.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-80.
26. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 1940-4.
27. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-11.
28. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.